Scarica l'app Stockscreener
5.78
3.67%
-0.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLDB Giù?
Forum
Previsione
Frazionamento azionario
Solid Biosciences Inc Borsa (SLDB) Ultime notizie
Q1 EPS Estimate for Solid Biosciences Increased by Analyst - Defense World
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here? - MSN
Bain Capital life sciences invests $4.03 million in Solid Biosciences By Investing.com - Investing.com
Solid Biosciences sees $20.15m stock purchase by Perceptive Advisors - Investing.com
Research Analysts Issue Forecasts for SLDB FY2025 Earnings - MarketBeat
Wedbush Increases Earnings Estimates for Solid Biosciences - MarketBeat
Chardan Capital Forecasts Strong Price Appreciation for Solid Biosciences (NASDAQ:SLDB) Stock - Defense World
Solid Biosciences’ stock soars on early success in DMD gene therapy trial - MSN
Solid Biosciences (NASDAQ:SLDB) Given New $16.00 Price Target at Chardan Capital - MarketBeat
Solid Biosciences’ $200 Million Common Stock Offering - Global Legal Chronicle
Wall Street’s Top Picks: Solid Biosciences, Wingstop, and Diamondback Energy - PUNE.NEWS
Wedbush Adjusts Price Target on Solid Biosciences to $18 From $16, Keeps Outperform Rating - Marketscreener.com
Solid Biosciences surges on Duchenne therapy success - The Pharma Letter
Solid Biosciences shares gain on JMP Market Outperform rating By Investing.com - Investing.com South Africa
Solid Biosciences shares gain on JMP Market Outperform rating - Investing.com India
Solid Biosciences CFO Kevin Tan sells $12,529 in stock By Investing.com - Investing.com Nigeria
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move? - MSN
Solid Biosciences' SWOT analysis: gene therapy stock poised for pivotal year - Investing.com Nigeria
Solid Biosciences Inc. (NASDAQ:SLDB) Receives $15.30 Average PT from Analysts - MarketBeat
Solid Biosciences Announces Pricing of Underwritten Offering - GlobeNewswire
Solid Biosciences CTO Herzich sells $10,644 in stock By Investing.com - Investing.com Australia
Solid Biosciences COO David Howton sells shares worth $22,021 By Investing.com - Investing.com Australia
Solid Biosciences chief regulatory officer sells shares for $12,192 By Investing.com - Investing.com South Africa
Solid Biosciences price target raised to $16 from $15 at Chardan - TipRanks
Solid Biosciences chief medical officer sells $12,893 in stock By Investing.com - Investing.com Canada
Solid Biosciences CEO Alexander Cumbo sells $45,005 in stock By Investing.com - Investing.com Australia
Solid Biosciences’ Gene Therapy SGT-003 Produces Microdystrophin Expression in Patients With DMD - CGTLive™
Solid Biosciences CFO Kevin Tan sells $12,529 in stock - Investing.com
Solid Biosciences CEO Alexander Cumbo sells $45,005 in stock - Investing.com
Solid Biosciences CTO Herzich sells $10,644 in stock - Investing.com
Solid Biosciences COO David Howton sells shares worth $22,021 - Investing.com India
Solid Biosciences Shares Up After Positive Results From Duchenne Drug Study, Prices $200 Million Offering - Marketscreener.com
Solid Biosciences stock soars on promising Duchenne therapy data By Investing.com - Investing.com South Africa
Solid Biosciences stock soars on promising Duchenne therapy data - Investing.com India
Early DMD gene therapy data powers Solid Bio stock surge - FirstWord Pharma
Top Midday Gainers -February 18, 2025 at 01:30 pm EST - Marketscreener.com
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data - Benzinga
As part of turnaround, Solid Bio reports promising initial data for Duchenne gene therapy - Endpoints News
Solid says early data suggest ‘differentiated’ Duchenne gene therapy - BioPharma Dive
Solid Biosciences sets $200 million stock and warrant offering By Investing.com - Investing.com Nigeria
Solid Biosciences jumps on early-stage data from gene therapy - TradingView
Biotech Boom: Solid Biosciences (SLDB) Stock Skyrockets On Positive Developments - Stocks Telegraph
Morning Brew: Marjorie Taylor Greene's Stock Moves and Solid Biosciences' Surge - GuruFocus.com
Duchenne gene therapy from Solid Biosciences produces promising results in early study - STAT
Solid Bio stock rises on data for Duchenne drug (SLDB:NASDAQ) - Seeking Alpha
Solid soars as early DMD gene therapy data beat expectations - Fierce Biotech
Solid Biosciences sets $200 million stock and warrant offering - Investing.com
Solid Biosciences Reports Positive Initial Clinical Data from SGT-003 -February 18, 2025 at 06:59 am EST - Marketscreener.com
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):